Skip to main content
SpringerLink
Log in

Prevention and treatment of postmenopausal osteoporosis

  • Chapter
Atlas of Postmenopausal Osteoporosis

Abstract

Due to the high personal and societal costs of osteoporosis, the condition remains a challenge to both public health and physicians [Kanis et al. 2008]. Furthermore, the rapid increase in the elderly population means that the prevention of osteoporotic fracture is a socioeconomic priority [Suzuki et al. 2008].

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 39.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 54.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  • Adami S, Giannini S, Bianchi G et al. Vitamin D status and response to treatment in post-menopausal osteoporosis. Osteoporos Int 2009; 20:239–44.

    Article  PubMed  CAS  Google Scholar 

  • American Association of Clinical Endocrinologists. Medical guidelines for clinical practice for the prevention and treatment of postmenopausal osteoporosis: 2001 edition, with selected updates for 2003. Endocr Pract 2003; 9:544–64.

    Article  Google Scholar 

  • Avenell A, Gillespie WJ, Gillespie LD et al. Vitamin D and vitamin D analogues for preventing fractures associated with involutional and post-menopausal osteoporosis. Cochrane Database Syst Rev 2005; 18:CD001880.

    Google Scholar 

  • Banciu M, Marza F, Ben Hadid R et al. Recent findings on the role of physical exercise in osteoporosis. Osteoporos Int 2005; 16:187.

    Google Scholar 

  • Baron R, Tsouderos Y. In vitro effects of S12911-2 on osteoclast function and bone marrow macrophage differentiation. Eur J Pharmacol 2002; 450:11–7.

    Article  PubMed  CAS  Google Scholar 

  • Barrett-Connor E, Grady D, Sashegyi A et al. Raloxifene and cardiovascular events in osteoporotic women: four-year results from the MORE (Multiple Outcomes of Raloxifene Evaluation) randomized trial. JAMA 2002; 287:847–57.

    Article  PubMed  CAS  Google Scholar 

  • Beral V, Million Women Study Collaborators. Breast cancer and hormonereplacement therapy in the Million Women Study. Lancet 2003; 362:419–27.

    Article  PubMed  CAS  Google Scholar 

  • Bischoff-Ferrari HA. How to select the doses of vitamin D in the management of osteoporosis. Osteoporos Int 2007; 18:401–7.

    Article  PubMed  CAS  Google Scholar 

  • Bischoff-Ferrari HA, Willett WC, Wong JB et al. Fracture prevention with vitamin D supplementation. JAMA 2005; 293:2257–64.

    Article  PubMed  CAS  Google Scholar 

  • Black DM, Cummings SR, Karpf DB et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Lancet 1996; 348:1535–41.

    Article  PubMed  CAS  Google Scholar 

  • Black DM, Delmas PD, Eastell R et al. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med 2007; 356:1809–22.

    Article  PubMed  CAS  Google Scholar 

  • Black DM, Schwartz AV, Ensrud KE et al. Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial. JAMA 2006; 296:2927–38.

    Article  PubMed  CAS  Google Scholar 

  • Bone HG, Bolognese MA, Yuen CK et al. Effects of denosumab on bone mineral density and bone turnover in postmenopausal women. J Clin Endocrinol Metab 2008; 93:2149–57.

    Article  PubMed  CAS  Google Scholar 

  • Bone HG, Hosking D, Devogelaer JP et al. Ten years experience with alendronate for osteoporosis in postmenopausal women. N Engl J Med 2004; 350:1189–99.

    Article  PubMed  CAS  Google Scholar 

  • Bonnelye E, Chabadel A, Saltel F et al. Dual effect of strontium ranelate: stimulation of osteoblast differentiation and inhibition of osteoclast formation and resorption in vitro. Bone 2008; 42:129–38.

    Article  PubMed  CAS  Google Scholar 

  • Boonen S, McClung M, Eastell R et al. Safety and efficacy of risedronate in reducing fracture risk in osteoporotic women aged 80 and older: implications for the use of antiresorptive agents in the old and oldest old. J Am Geriatr Soc 2004; 52:1832–9.

    Article  PubMed  Google Scholar 

  • Boonen S, Lips P, Bouillon R et al. Need for additional calcium to reduce the risk of hip fracture with vitamin D supplementation: evidence from a comparative meta-analysis of randomized controlled trials. J Clin Endocrinol Metab. 2007; 92:1415–23.

    Article  PubMed  CAS  Google Scholar 

  • Brown JP, Josse RG. 2002 clinical practice guidelines for the diagnosis and management of osteoporosis in Canada. CMAJ 2002; 167(Suppl 10):S1–S34.

    PubMed  Google Scholar 

  • Bruyère O, Malaise, Neuprez A et al. European postmenopausal women have high prevalence of vitamin D inadequacy. Arthritis Rheum 2006; 54:S585.

    Article  Google Scholar 

  • Bruyere O, Roux C, Detilleux J et al. Relationship between bone mineral density changes and fracture risk reduction in patients treated with strontium ranelate. J Clin Endocrinol Metab. 2007; 92:3076–81.

    Article  PubMed  CAS  Google Scholar 

  • Canalis E, Hott M, Deloffre P et al. The divalent strontium salt S12911 enhances bone cell replication and bone formation in vitro. Bone 1996; 18:517–23.

    Article  PubMed  CAS  Google Scholar 

  • Cauley JA, Robbins J, Chen Z et al. Effects of estrogen plus progestin on risk of fracture and bone mineral density. The Women’s Health Initiative Randomized Trial. JAMA 2003; 290:1729–38.

    Article  PubMed  CAS  Google Scholar 

  • Chapuy MC, Arlot ME, Duboeuf F et al. Vitamin D3 and calcium to prevent hip fractures in the elderly women. N Engl J Med 1992; 327:1637–42.

    Article  PubMed  CAS  Google Scholar 

  • Chapuy MC, Pamphile R, Paris E et al. Combined calcium and vitamin D3 supplementation in elderly women: confirmation of reversal of secondary hyperparathyroidism and hip fracture risk: the Decalyos II study. Osteoporos Int 2002; 13:257–64.

    Article  PubMed  CAS  Google Scholar 

  • Chesnut CH 3rd, Silverman S, Andriano K et al. A randomised trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: the Prevent Recurrence of Osteoporotic Fractures Study. Am J Med 2000; 109:267–76.

    Article  PubMed  CAS  Google Scholar 

  • Chesnut III CH, Skag A, Christiansen C. Oral Ibandronate Osteoporosis Vertebral Fracture Trial in North America and Europe (BONE). Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis. J Bone Miner Res 2004; 19:1241–9.

    Article  PubMed  CAS  Google Scholar 

  • Choi HJ, Im JA, Kim SH. Changes in bone markers after once-weekly low-dose alendronate in postmenopausal women with moderate bone loss. Maturitas 2008; 60:170–6.

    Article  PubMed  CAS  Google Scholar 

  • Cranney A, Tugwell P, Adachi J et al. Meta-analyses of therapies for postmenopausal osteoporosis. III. Meta-analysis of risedronate for the treatment of postmenopausal women. Endocr Rev 2002a; 23:517–23.

    Article  PubMed  CAS  Google Scholar 

  • Cranney A, Wells G, Willan A et al. Meta-analyses of therapies for postmenopausal osteoporosis. II. Meta-analysis of alendronate for the treatment of postmenopausal women. Endocr Rev 2002b; 23:508–16.

    Article  PubMed  CAS  Google Scholar 

  • Cranney A, Wells GA, Yetisir E et al. Ibandronate for the prevention of nonvertebral fractures: a pooled analysis of individual patient data. Osteoporos Int 2009; 20:291–7.

    Article  PubMed  CAS  Google Scholar 

  • Cummings SR, Black DM, Thompson DE et al. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures. JAMA 1998; 280:2077–82.

    Article  PubMed  CAS  Google Scholar 

  • Cummings SR, Ettinger B, Delmas PD et al. The effects of tibolone in older postmenopausal women. N Engl J Med 2008; 359:697–708.

    Article  PubMed  CAS  Google Scholar 

  • Cummings SR, San Martin J, McClung MR et al. FREEDOM Trial. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med 2009; 361:756–65.

    Article  PubMed  CAS  Google Scholar 

  • Dawson-Hughes B, Heaney RP, Holick MF et al. Estimates of optimal vitamin D status. Osteoporos Int 2005; 16:713–6.

    Article  PubMed  CAS  Google Scholar 

  • Delmas PD. Treatment of postmenopausal osteoporosis. Lancet 2002; 359:2018–26.

    Article  PubMed  CAS  Google Scholar 

  • Delmas PD, Adami S, Strugala C et al. Intravenous ibandronate injections in postmenopausal women with osteoporosis: one-year results from the Dosing Intravenous Administration Study. Arthritis Rheum 2006a; 54:1838–46.

    Article  PubMed  CAS  Google Scholar 

  • Delmas PD, Bjarnason NH, Mitlak BH et al. Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women. N Engl J Med 1997; 337:1641–7.

    Article  PubMed  CAS  Google Scholar 

  • Delmas PD, Ensrud KE, Adachi JD et al. Efficacy of raloxifene on vertebral fracture risk reduction in postmenopausal women with osteoporosis: four-year results from a randomized clinical trial. J Clin Endocrinol Metab 2002; 87:3609–17.

    Article  PubMed  CAS  Google Scholar 

  • Delmas PD, Genant HK, Crans GG et al. Severity of prevalent vertebral fractures and the risk of subsequent vertebral and nonvertebral fractures: results from the MORE trial. Bone 2003; 33:522–32.

    Article  PubMed  CAS  Google Scholar 

  • Delmas PD, Licata AA, Reginster JY et al. Fracture Risk reduction during treatment with teriparatide is independent of pre-treatment bone turnover. Bone 2006b; 39:237–43.

    Article  PubMed  CAS  Google Scholar 

  • Delmas PD, Recker RR, Chesnut CH 3rd et al. Daily and intermittent oral ibandronate normalize bone turnover and provide significant reduction in vertebral fracture risk: results from the BONE study. Osteoporos Int 2004; 15:792–8.

    Article  PubMed  CAS  Google Scholar 

  • Eastell R. Treatment of postmenopausal osteoporosis. N Engl J Med 1998; 338:736–46.

    Article  PubMed  CAS  Google Scholar 

  • Egger P, Duggleby S, Hobbs R et al. Cigarette smoking and bone mineral density in the elderly. J Epidemiol Community Health 1996; 50:47–50.

    Article  PubMed  CAS  Google Scholar 

  • Ernst E. Exercise for female osteoporosis. A systematic review of randomised clinical trials. Sports Med 1998; 25:359–68.

    Article  PubMed  CAS  Google Scholar 

  • Ettinger B, Black DM, Mitlak BH et al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. JAMA 1999; 282:637–45.

    Article  PubMed  CAS  Google Scholar 

  • Gardella TJ, Jüppner H. Molecular properties of the PTH/PTHrP receptor. Trends Endocrinol Metab 2001; 12:210–7.

    Article  PubMed  CAS  Google Scholar 

  • Going S, Lohman T, Houtkooper L et al. Effects of exercise on bone mineral density in calcium-replete postmenopausal women with and without hormone replacement therapy. Osteoporos Int 2003; 14:637–643.

    Article  PubMed  CAS  Google Scholar 

  • Greenspan SL, Bone HG, Ettinger MP et al. Effect of recombinant human parathyroid hormone (1–84) on vertebral fracture and bone mineral density in postmenopausal women with osteoporosis: a randomized trial. Annals Int Med 2007; 146:326–39.

    Article  Google Scholar 

  • Grosso A, Douglas I, Hingorani A et al. Post-marketing assessment of the safety of strontium ranelate; a novel case-only approach to the early detection of adverse drug reactions. Br J Clin Pharmacol 2008; 66:689–94.

    PubMed  CAS  Google Scholar 

  • Hansen MA, Overgaard K, Riis BJ et al. Potential risk factors for development of postmenopausal osteoporosis—examined over a 12-year period. Osteoporos Int 1991; 1:95–102.

    Article  PubMed  CAS  Google Scholar 

  • Harris ST, Blumentals WA, Miller PD. Ibandronate and the risk of non-vertebral and clinical fractures in women with postmenopausal osteoporosis: results of a meta-analysis of phase III studies. Curr Med Res Opin 2008; 24:237–45.

    Article  PubMed  CAS  Google Scholar 

  • Harris ST, Watts NB, Genant HK et al. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis. A randomised controlled trial. JAMA 1999; 282:1344–52.

    Article  PubMed  CAS  Google Scholar 

  • Heikinheimo RJ, Inkovaara JA, Harju EJ et al. Annual injection of vitamin D and fractures of aged bones. Calcif Tissue Int 1992; 51:105–10.

    Article  PubMed  CAS  Google Scholar 

  • Hodsman AB, Bauer DC, Dempster DW et al. Parathyroid hormone and teriparatide for the treatment of osteoporosis: a review of the evidence and suggested guidelines for its use. Endo Rev 2005; 26:688–703.

    Article  CAS  Google Scholar 

  • Hodsman AB, Hanley, Ettinger MP et al. Efficacy and safety of human parathyroid hormone (1–84) in increasing bone mineral density in postmenopausal osteoporosis. J Clin End Metab 2003; 88:5212–20.

    Article  CAS  Google Scholar 

  • Hotta M, Shibasaki T, Sato K et al. The importance of body weight history in the occurrence and recovery of osteoporosis in patients with anorexia nervosa: evaluation by dual X-ray absorptiometry and bone metabolic markers. Eur J Endocrinol 1998; 139:276–83.

    Article  PubMed  CAS  Google Scholar 

  • Hurtel Lemaire AS, Mentaverri R, Caudrillier A et al. The calcium-sensing receptor is involved in strontium ranelate-induced osteoclast apoptosis. New insights into the associated signaling pathways. J Biol Chem 2009; 284:575–84.

    Article  PubMed  CAS  Google Scholar 

  • Jilka RL, Weinstein RS, Bellido T et al. Increased bone formation by prevention of osteoblast apoptosis with parathyroid hormone. J Clin Invest 1999; 104:371–373.

    Article  Google Scholar 

  • Kanis JA, Burlet N, Cooper C et al. European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int 2008; 19:399–428.

    Article  PubMed  CAS  Google Scholar 

  • Kiel DP, Baron JA, Anderson JJ et al. Smoking eliminates the protective effect of oral estrogens on the risk for hip fracture among women. Ann Intern Med 1992; 116:716–21.

    Article  PubMed  CAS  Google Scholar 

  • Lau E, Papaioannou A, Dolovich L et al. Patients’ adherence to osteoporosis therapy: exploring the perceptions of postmenopausal women. Can Fam Physician 2008; 54:394–402.

    PubMed  Google Scholar 

  • Lewiecki EM, Keaveny TM, Kopperdahl D et al. Once-monthly oral lbandronate improves biomechanical determinants of bone strength in women with postmenopausal osteoporosis. J Clin Endocrinol Metab 2009; 94:171–80.

    Article  PubMed  CAS  Google Scholar 

  • Lindsay R, Scheels WH, Neer R et al. Sustained vertebral fracture risk reduction after withdrawal of teriparatide (recombinant human parathyroid hormone (1–34)) in postmenopausal women with osteoporosis. Arch Intern Med 2004; 164:2024–30.

    Article  PubMed  Google Scholar 

  • Lyles KW, Colon-Emeric CS, Magaziner JS et al. Zoledronic acid and clinical fractures and mortality after hip fracture. N Engl J Med 2007; 357:1799–1809.

    Article  PubMed  CAS  Google Scholar 

  • Malabanan A, Veronikis IE, Holick MF. Redefining vitamin D insufficiency. Lancet 1998; 351:805–6.

    Article  PubMed  CAS  Google Scholar 

  • Marcus R, Wang O, Satterwhite J et al. The skeletal response to teriparatide is largely independent of age, initial bone mineral density, and prevalent vertebral fractures in postmenopausal women with osteoporosis. J Bone Miner Res 2003; 18:18–23.

    Article  PubMed  CAS  Google Scholar 

  • Marie PJ, Ammann P, Boivin G et al. Mechanisms of action and therapeutical potential of strontium in bone. Calcif Tissue Int 2001; 69:121–129.

    Article  PubMed  CAS  Google Scholar 

  • Martino S, Cauley JA, Barrett-Connor E et al; CORE Investigators. Continuing outcomes relevant to Evista: breast cancer incidence in postmenopausal osteoporotic women in a randomized trial of raloxifene. J Natl Cancer Inst 2004; 96:1751–61.

    Article  PubMed  CAS  Google Scholar 

  • Mashiba T, Hirano T, Turner CH et al. Suppressed bone turnover by bisphosphonates increases microdamage accumulation and reduces some biomechanical properties in dog rib. J Bone Miner Res 2000; 15:613–20.

    Article  PubMed  CAS  Google Scholar 

  • Mastaglia SR, Pellegrini GG, Mandalunis PM et al. Vitamin D insufficiency reduces the protective effect of bisphosphonate on ovariectomy-induced bone loss in rats. Bone 2006; 39:837–44.

    Article  PubMed  CAS  Google Scholar 

  • McClung MR. Bisphosphonates. Endcrinol Metab Clin North Am 2003; 32:253–71.

    Article  CAS  Google Scholar 

  • McClung MR, Geusens P, Miller PD et al. Effect of risedronate on the risk of hip fracture in elderly women. N Engl J Med 2001; 344:333–40.

    Article  PubMed  CAS  Google Scholar 

  • McClung MR, Lewiecki EM, Cohen SB et al. Denosumab in postmenopausal women with low bone mineral density. N Engl J Med 2006; 354:821–31.

    Article  PubMed  CAS  Google Scholar 

  • Meunier PJ, Roux C, Seeman E et al. The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis. N Engl J Med 2004; 350:459–68.

    Article  PubMed  CAS  Google Scholar 

  • Miller PD, Bolognese MA, Lewiecki EM et al. Effect of denosumab on bone density and turnover in postmenopausal women with low bone mass after longterm continued, discontinued, and restarting of therapy: a randomized blinded phase 2 clinical trial. Bone 2008; 43:222–9.

    Article  PubMed  CAS  Google Scholar 

  • Mundy GR. Osteoporosis: pathophysiology and nonpharmacological management. Best Pract Res Clin Rheumatol 2001; 15:727–45.

    Article  PubMed  CAS  Google Scholar 

  • Neer RM, Arnaud CD, Zanchetta JR et al. Effect of parathyroid hormone (I-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 2001; 344:1434–41.

    Article  PubMed  CAS  Google Scholar 

  • Neuprez A, Reginster JY. Bone-forming agents in the management of osteoporosis. Best Practice & Research Clinical Endocrinology & Metabolism 2008; 22:869–83.

    Article  CAS  Google Scholar 

  • Prince RL, Devine A, Dhaliwal SS et al. Effects of calcium supplementation on clinical fracture and bone structure. Arch Intern Med 2006; 166:869–75.

    Article  PubMed  CAS  Google Scholar 

  • Prince R, Sipos A, Hossain A et al. Sustained nonvertebral fragility fracture risk reduction after discontinuation of teriparatide treatment. J Bone Miner Res 2005; 20:1507–13.

    Article  PubMed  CAS  Google Scholar 

  • Rabenda V, Vanoverloop J, Fabri V et al. Low incidence of anti-osteoporosis treatment after hip fracture. J Bone Joint Surg Am 2008; 90:2142–8.

    Article  PubMed  Google Scholar 

  • Reginster JY, Adami S, Lakatos P et al. Efficacy and tolerability of once-monthly oral ibandronate in postmenopausal osteoprosis: 2-year results from the MOBILE study. Ann Rheum Dis 2006; 65:654–61.

    Article  PubMed  CAS  Google Scholar 

  • Reginster JY, Deroisy R, Lecart MP et al. A double-blind, placebo-controlled, dose-finding trial of intermittent nasal salmon calcitonin for prevention of postmenopausal lumbar spine bone loss. Am J Med 1995; 98:452–8.

    Article  PubMed  CAS  Google Scholar 

  • Reginster JY, Felsenberg D, Boonen S et al. Effects of long-term strontium ranelate treatment on the risk of nonvertebral and vertebral fractures in postmenopausal osteoporosis: Results of a five-year, randomized, placebo controlled trial. Arthritis Rheum 2008a; 58:687–95.

    Google Scholar 

  • Reginster JY, Franchimont P. Side effect of SSCT given by intranasal spray compared with intra-muscular injection. Clin Exp Rheumatol 1985; 3:155–7.

    PubMed  CAS  Google Scholar 

  • Reginster JY, Malaise O, Neuprez A et al. Strontium ranelate in the prevention of osteoporotic fractures. Int J Clin Pract 2007; 61:324–8.

    Article  PubMed  CAS  Google Scholar 

  • Reginster JY, Minne HW, Sorensen OH et al. Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Osteoporos Int 2000; 11:83–91.

    Article  PubMed  CAS  Google Scholar 

  • Reginster JY, Sawicki A, Roces-Varela et al. Long-term treatment of postmenopausal osteoporosis with strontium ranelate: results at 8 years. Bone 2009; in press.

    Google Scholar 

  • Reginster JY, Seeman E, De Vernejoul MC et al. Strontium ranelate reduces the risk of nonvertebral fractures in postmenopausal women with osteoporosis: treatment of peripheral osteoporosis (TROPOS) study. J Clin Endocrinol Metab 2005; 90:2816–22.

    Article  PubMed  CAS  Google Scholar 

  • Reginster JY, Spector T, Badurski J et al. A short-term run-in study can significantly contribute to increasing the quality of long-term osteoporosis trials. The strontium ranelate phase III program. Osteoporos Int 2002; 13(S1):S30.

    Google Scholar 

  • Reginster JY, Taquet AN, Fraikin G et al. Parathyroid hormone in the treatment of involutional osteoporosis: back to the future. Osteoporos Int 1997; 7:S163–7.

    Article  PubMed  Google Scholar 

  • Reid DM, Hosking D, Kendler D et al. A comparison of the effect of alendronate and risedronate on bone mineral density in postmenopausal women with osteoporosis: 24-month results from FACTS-International. Int J Clin Pract 2008; 62:575–84.

    Article  PubMed  CAS  Google Scholar 

  • Riggs BL, Hartmann LC. Selective estrogen-receptor modulators — mechanisms of action and application to clinical practice. N Engl J Med 2003; 348:618–29.

    Article  PubMed  CAS  Google Scholar 

  • Rizzoli R, Boonen S, Brandi ML et al. The role of calcium and vitamin D in the management of osteoporosis. Bone 2008a; 42:246–9.

    Article  PubMed  CAS  Google Scholar 

  • Rizzoli R, Burlet N, Cahall D et al. Osteonecrosis of the jaw and bisphosphonates treatment for osteoporosis. Bone 2008b; 42:841–7.

    Article  PubMed  CAS  Google Scholar 

  • Rossouw JE, Anderson GL, Prentice RL et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women’s Health Initiative randomized controlled trial. JAMA 2002; 288:321–33.

    Article  PubMed  CAS  Google Scholar 

  • Roux C, Reginster JY, Fechtenbaum J et al. Vertebral fracture risk reduction with strontium ranelate in women with postmenopausal osteoporosis is independent of baseline risk factors. J Bone Miner Res 2006; 21:536–42.

    Article  PubMed  CAS  Google Scholar 

  • Rubin MR, Bilezikian JP. New anabolic therapies in osteoporosis. Endocrinol Metab Clin North Am 2003; 32:285–307.

    Article  PubMed  CAS  Google Scholar 

  • Sahota O, Mundey MK, San P et al. The relationship between vitamin D and parathyroid hormone: calcium homeostasis, bone turnover, and bone mineral density in postmenopausal women with established osteoporosis. Bone 2004; 35:312–9.

    Article  PubMed  CAS  Google Scholar 

  • Seeman E, Devogelaer J, Lorenc R et al. Strontium ranelate reduces the risk of vertebral fractures in patients with osteopenia. J Bone Miner Res 2008; 23:433–8.

    Article  PubMed  CAS  Google Scholar 

  • Seeman E, Vellas B, Benhamou C et al. Strontium ranelate reduces the risk of vertebral and nonvertebral fractures in women eighty years of age and older. J Bone Miner Res 2006; 21:1113–20.

    Article  PubMed  CAS  Google Scholar 

  • Shea B, Wells G, Cranney A et al. Osteoporosis Methodology Group; Osteoporosis Research Advisory Group. Calcium supplementation on bone loss in postmenopausal women. Cochrane Database Syst Rev 2004;(1):CD004526.

    Google Scholar 

  • Shea B, Wells G, Cranney A et al. Meta-analysis of calcium supplementation for the prevention of postmenopausal osteoporosis. Endocrine Reviews 2002; 23:552–9.

    Article  PubMed  CAS  Google Scholar 

  • Shrader SP, Raggucci KR. Parathyroid hormone (1-84) and treatment of osteoporosis. Annals Pharmacotherapy 2005; 39:1511–6.

    Article  CAS  Google Scholar 

  • Silverman SL, Watts NB, Delmas PD et al. Effectiveness of bisphosphonates on nonvertebral and hip fractures in the first year of therapy: the risedronate and alendronate (REAL) cohort Study. Osteoporos Int 2007; 18:25–34.

    Article  PubMed  CAS  Google Scholar 

  • Suzuki A, Sekiguchi S, Asano S et al. Pharmacological topics of bone metabolism: recent advances in pharmacological management of osteoporosis. J Pharmacol Sci 2008; 106:530–5.

    Article  PubMed  CAS  Google Scholar 

  • Takahashi N, Sasaki T, Tsouderos Y et al. S 12911-2 inhibits osteoclastic bone resorption in vitro. J Bone Miner Res 2003; 18:1082–7.

    Article  PubMed  CAS  Google Scholar 

  • Tilyard MW, Spears GF, Thomson J et al. Treatment of postmenopausal osteoporosis with calcitriol or calcium. N Engl J Med 1992; 326:357–62.

    Article  PubMed  CAS  Google Scholar 

  • Torgerson DJ, Bell-Syer SE. Hormone replacement therapy and prevention of nonvertebral fractures. A meta-analysis of randomised trials. JAMA 2001a; 285:2891–7.

    Article  PubMed  CAS  Google Scholar 

  • Torgerson DJ, Bell-Syer SE. Hormone replacement therapy and prevention of vertebral fractures: a meta-analysis of randomised trials. BMC Musculoskelet Disord 2001b; 2:7.

    Article  PubMed  CAS  Google Scholar 

  • Tosteson AN, Burge RT, Marshall DA et al. Therapies for treatment of osteoporosis in US women: cost-effectiveness and budget impact considerations. Am J Manag Care 2008; 14:605–15.

    PubMed  Google Scholar 

  • Ward KD, Klesges RC. A meta-analysis of the effects of cigarette smoking on bone mineral density. Calcif Tissue Int 2001; 68:259–70.

    Article  PubMed  CAS  Google Scholar 

  • Watts NB. Bisphosphonate treatment of osteoporosis. Clin Geriatr Med 2003; 19:395–414.

    Article  PubMed  Google Scholar 

  • Watts NB. Bisphosphonate treatment for osteoporosis. In: The Osteoporotic Syndrome. Edited by LV Avioli. San Diego: Academic Press, 2000;121–32.

    Chapter  Google Scholar 

  • Wehren LE. The epidemiology of osteoporosis and fractures in geriatric medicine. Clin Geriatr Med 2003; 19:245–58.

    Article  PubMed  Google Scholar 

  • Winner SJ, Morgan CA, Evans JG. Perimenopausal risk of falling and incidence of distal forearm fracture. BMJ 1989; 298:1486–8.

    Article  PubMed  CAS  Google Scholar 

  • Woodis CB. Once-yearly administered intravenous zoledronic acid for postmenopausal osteoporosis. Ann Pharmacother 2008; 42:1085–9.

    Article  PubMed  CAS  Google Scholar 

Download references

Authors
  1. Audrey Neuprez
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jean-Yves Reginster
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Division of Bone Diseases, Department of Rehabilitation and Geriatrics, University Hospitals, Faculty of Medicine, Geneva, Switzerland

    René Rizzoli

Rights and permissions

Reprints and permissions

Copyright information

© 2010 Current Medicine Group

About this chapter

Cite this chapter

Neuprez, A., Reginster, JY. (2010). Prevention and treatment of postmenopausal osteoporosis. In: Rizzoli, R. (eds) Atlas of Postmenopausal Osteoporosis. Springer Healthcare, Tarporley. https://doi.org/10.1007/978-1-907673-28-3_4

Download citation

  • DOI: https://doi.org/10.1007/978-1-907673-28-3_4

  • Publisher Name: Springer Healthcare, Tarporley

  • Print ISBN: 978-1-85873-443-9

  • Online ISBN: 978-1-907673-28-3

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation